A Multicenter, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High-Risk Basal Cell Carcinoma.

clinicaltrials.gov/study/NCT06422936?term=BO-112&rank=7

Independent

Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma.

clinicaltrials.gov/study/NCT04570332?term=BO-112&rank=5

Independent

Colorectal or Gastric/​GEJ Cancer With Liver Metastasis

Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer

clinicaltrials.gov/study/NCT04508140?term=BO-112&rank=6

Independent

An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment.

clinicaltrials.gov/study/NCT02828098?term=BO-112&rank=2

Independent

Open-label Clinical Study of Intratumoral Administration of BO-112 in Combination With Radiotherapy and Nivolumab in Patients With Metastatic PD- 1/PD-L1 Refractory Non-small Cell Lung Cancer

clinicaltrials.gov/study/NCT05265650?term=BO-112&rank=3

Clínica Universidad de Navarra, Universidad de Navarra

Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma

clinicaltrials.gov/study/NCT04420975?term=BO-112&rank=4

Jonsson Comprehensive Cancer Center

Pilot Feasibility Study of Intratumoral BO-112 in Combination With Pembrolizumab for Advanced Hepatocellular Carcinoma

clinicaltrials.gov/study/NCT04777708?term=BO-112&rank=1

Jonsson Comprehensive Cancer Center